Phathom Pharmaceuticals, Inc. PHAT
5.74 USD -0.17 (-2.96%)
At closeNov 3, 2026, 4:06 PM EST
5.74 0.00 0.00%
After hours · Nov 3, 4:06 PM ET
5.50 Day range 6.11
5.02 52-week range 18.31
- YTD
- -65.40%
- 1 year
- -58.19%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 23.70 +312.9% upside
Now 5.74
- Target (low)
- 13.00
- Target (mean)
- 23.70
- Target (high)
- 29.00
Ratings (0m) 11 10 buy · 1 hold · 0 sell
- Strong buy2
- Buy8
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 11
- 3 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.1954 | -0.24 – -0.17 | -1.07 | +81.7% | 58.63M | +105.6% | 5 |
| Next quarter | -0.0794 | -0.13 – -0.04 | -0.79 | +89.9% | 74.59M | +88.8% | 5 |
| Current year | 0.01275 | -0.18 – 0.28 | -2.06 | +100.6% | 332.04M | +89.6% | 4 |
| Next year | 1.54 | 1.11 – 2.25 | 0.01275 | +12011.4% | 528.17M | +59.1% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 27, 2026 | Barclays | Upgrade | Equal-Weight | Overweight |
| Feb 27, 2026 | Guggenheim | Maintained | Buy | Buy |
| Dec 9, 2025 | Barclays | Initiated | — | Equal-Weight |
| Oct 31, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 9, 2025 | Craig-Hallum | Maintained | Buy | Buy |
| Jun 9, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 6, 2025 | Needham | Maintained | Buy | Buy |
| May 2, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| May 2, 2025 | Guggenheim | Maintained | Buy | Buy |
| May 2, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 2, 2025 | Craig-Hallum | Maintained | Buy | Buy |
| Apr 21, 2025 | Needham | Reiterated | Buy | Buy |
| Apr 17, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Apr 9, 2025 | Needham | Reiterated | Buy | Buy |
| Apr 2, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Apr 2, 2025 | Needham | Reiterated | Buy | Buy |
| Mar 10, 2025 | Goldman Sachs | Maintained | Neutral | Neutral |
| Mar 7, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 6, 2025 | Needham | Reiterated | Buy | Buy |
| Jan 10, 2025 | Needham | Reiterated | Buy | Buy |
| Dec 12, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 11, 2024 | Needham | Reiterated | Buy | Buy |
| Sep 13, 2024 | Needham | Reiterated | Buy | Buy |
| Sep 6, 2024 | Needham | Reiterated | Buy | Buy |
| Aug 30, 2024 | Needham | Reiterated | Buy | Buy |
| Aug 23, 2024 | Needham | Reiterated | Buy | Buy |
| Aug 19, 2024 | Needham | Reiterated | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 12, 2024 | Needham | Reiterated | Buy | Buy |
| Aug 9, 2024 | Goldman Sachs | Maintained | Neutral | Neutral |